Neurocrine Biosciences Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
© -
We're ready. Hi, there. My name is Evan Seigerman, and I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And with me today, we have Neurocrine Biosciences. And representing Neurocrine, we have Matt Abernethy, the CFO. Before we get started, I think you have a few comments.
Yes, sure. Thanks, Evan, and thank you to you and Crédit Suisse for inviting us to this year's health care conference.
Before I begin, I will be making forward-looking statements. So I would direct you to our latest SEC filings for the related risk factors and uncertainties associated with our company and then also our industry. Evan, before we jump into the Q&A, I thought it may make sense for me to just give a brief overview of who Neurocrine is for those not as familiar with our story.
So Neurocrine has been around for quite some time, over 25 years, with a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |